O	0	1	A
O	2	7	pilot
O	8	18	randomized
O	19	24	trial
O	25	27	to
O	28	35	prevent
B-condition	36	42	sexual
I-condition	43	54	dysfunction
O	55	57	in
B-eligibility	58	72	postmenopausal
I-eligibility	73	79	breast
I-eligibility	80	86	cancer
I-eligibility	87	96	survivors
I-eligibility	97	105	starting
I-eligibility	106	114	adjuvant
I-eligibility	115	124	aromatase
I-eligibility	125	134	inhibitor
I-eligibility	135	142	therapy
O	142	143	.

O	144	145	A
O	146	156	randomized
O	157	162	pilot
O	163	168	trial
O	169	178	evaluated
O	179	182	the
O	183	193	hypothesis
O	194	198	that
O	199	204	early
O	205	217	intervention
O	218	225	lessens
O	226	232	sexual
O	233	244	dysfunction
O	245	247	in
O	248	251	the
O	252	257	first
O	258	262	year
O	263	265	on
O	266	275	aromatase
O	276	286	inhibitors
O	286	287	.

O	288	289	A
O	290	299	secondary
O	300	303	aim
O	304	307	was
O	308	317	comparing
O	318	321	the
O	322	330	efficacy
O	331	333	of
O	334	337	two
O	338	345	vaginal
O	346	358	moisturizers
O	358	359	.

B-total-participants	360	365	Fifty
I-total-participants	365	366	-
I-total-participants	366	371	seven
B-eligibility	372	386	postmenopausal
I-eligibility	387	392	women
I-eligibility	393	397	with
I-eligibility	398	403	early
I-eligibility	404	409	stage
I-eligibility	410	416	breast
I-eligibility	417	423	cancer
I-eligibility	424	432	starting
I-eligibility	433	442	aromatase
I-eligibility	443	453	inhibitors
O	454	458	were
O	459	469	randomized
O	470	472	to
O	473	478	three
O	479	488	treatment
O	489	495	groups
O	495	496	.

O	497	500	All
O	501	509	received
O	510	511	a
O	512	519	handout
O	520	522	on
O	523	531	managing
O	532	538	sexual
O	539	542	and
O	543	548	other
O	549	553	side
O	554	561	effects
O	561	562	.

O	563	566	The
B-control	567	572	Usual
I-control	573	577	Care
I-control	578	583	group
O	584	592	received
O	593	595	no
O	596	606	additional
O	607	614	therapy
O	614	615	.

O	616	619	The
O	620	626	Active
O	627	636	Treatment
O	637	643	groups
O	644	652	received
O	653	654	a
O	655	656	6
O	656	657	-
O	657	662	month
O	663	669	supply
O	670	672	of
O	673	674	a
B-intervention	675	682	vaginal
I-intervention	683	694	moisturizer
O	695	696	(
O	696	706	hyaluronic
O	707	711	acid
O	711	712	-
O	712	717	based
O	718	720	in
O	721	727	Active
O	728	733	Group
O	733	734	-
O	734	735	H
O	736	739	and
O	740	749	prebiotic
O	750	752	in
O	753	759	Active
O	760	765	Group
O	765	766	-
O	766	767	P
O	767	768	)
O	769	772	and
O	773	774	a
B-intervention	775	782	vaginal
I-intervention	783	792	lubricant
I-intervention	793	796	and
I-intervention	797	804	dilator
I-intervention	804	805	,
I-intervention	806	810	plus
I-intervention	811	817	access
I-intervention	818	820	to
I-intervention	821	823	an
I-intervention	824	835	educational
I-intervention	836	843	website
I-intervention	844	847	and
I-intervention	848	853	phone
I-intervention	854	862	coaching
O	862	863	.

O	864	878	Questionnaires
O	879	888	completed
O	889	891	at
O	892	900	baseline
O	900	901	,
O	902	903	6
O	903	904	,
O	905	908	and
O	909	911	12
O	912	918	months
O	919	927	included
O	928	931	the
O	932	938	Female
O	939	945	Sexual
O	946	954	Function
O	955	960	Index
O	961	962	(
O	962	966	FSFI
O	966	967	)
O	967	968	,
O	969	979	Menopausal
O	980	986	Sexual
O	987	995	Interest
O	996	1009	Questionnaire
O	1010	1011	(
O	1011	1015	MSIQ
O	1015	1016	)
O	1016	1017	,
O	1018	1024	Female
O	1025	1031	Sexual
O	1032	1040	Distress
O	1041	1046	Scale
O	1046	1047	-
O	1047	1054	Revised
O	1055	1056	(
O	1056	1060	FSDS
O	1060	1061	-
O	1061	1062	R
O	1062	1063	)
O	1063	1064	,
O	1065	1068	and
O	1069	1070	a
O	1071	1081	menopausal
O	1082	1089	symptom
O	1090	1095	scale
O	1095	1096	.

B-total-participants	1097	1102	Forty
I-total-participants	1102	1103	-
I-total-participants	1103	1107	nine
O	1108	1113	women
O	1114	1115	(
O	1115	1117	86
O	1117	1118	%
O	1118	1119	)
O	1120	1128	provided
O	1129	1135	follow
O	1135	1136	-
O	1136	1138	up
O	1139	1143	data
O	1143	1144	.

B-age	1145	1149	Mean
I-age	1150	1153	age
I-age	1154	1157	was
I-age	1158	1160	59
O	1161	1164	and
O	1165	1167	77
O	1167	1168	%
O	1169	1173	were
B-ethinicity	1174	1177	non
I-ethinicity	1177	1178	-
I-ethinicity	1178	1186	Hispanic
I-ethinicity	1187	1196	Caucasian
O	1196	1197	.

B-outcome	1198	1204	Sexual
I-outcome	1205	1213	function
O	1214	1217	was
O	1218	1226	impaired
O	1227	1229	at
O	1230	1238	baseline
O	1238	1239	,
O	1240	1243	but
O	1244	1252	remained
O	1253	1259	stable
O	1260	1264	over
O	1265	1267	12
O	1268	1274	months
O	1275	1278	for
O	1279	1282	all
O	1283	1289	groups
O	1289	1290	.

O	1291	1294	The
O	1295	1303	combined
O	1304	1310	active
O	1311	1320	treatment
O	1321	1326	group
O	1327	1330	had
B-outcome	1331	1335	less
I-outcome	1336	1347	dyspareunia
O	1348	1349	(
O	1349	1350	P
O	1351	1352	=
O	1353	1354	0
O	1354	1355	.
O	1355	1357	07
O	1357	1358	)
O	1359	1362	and
B-outcome	1363	1369	sexual
I-outcome	1370	1378	distress
O	1379	1380	(
O	1380	1381	P
O	1382	1383	=
O	1384	1385	0
O	1385	1386	.
O	1386	1388	02
O	1388	1389	)
O	1390	1392	at
O	1393	1394	6
O	1395	1401	months
O	1402	1406	than
O	1407	1410	the
O	1411	1416	Usual
O	1417	1421	Care
O	1422	1427	group
O	1427	1428	.

O	1429	1431	At
O	1432	1433	6
O	1434	1440	months
O	1440	1441	,
O	1442	1445	the
O	1446	1452	Active
O	1452	1453	-
O	1453	1454	H
O	1455	1460	group
O	1461	1469	improved
O	1470	1483	significantly
O	1484	1488	more
O	1489	1493	than
O	1494	1497	the
O	1498	1504	Active
O	1504	1505	-
O	1505	1506	P
O	1507	1512	group
O	1513	1515	on
B-outcome	1516	1520	FSFI
I-outcome	1521	1526	total
I-outcome	1527	1532	score
O	1533	1534	(
O	1534	1535	P
O	1536	1537	=
O	1538	1539	0
O	1539	1540	.
O	1540	1542	04
O	1542	1543	)
O	1543	1544	.

O	1545	1551	Sexual
O	1552	1562	counseling
O	1563	1569	helped
O	1570	1575	women
O	1576	1584	maintain
B-outcome	1585	1591	stable
I-outcome	1592	1598	sexual
I-outcome	1599	1607	function
O	1608	1610	on
O	1611	1620	aromatase
O	1621	1631	inhibitors
O	1631	1632	.

O	1633	1639	Active
O	1640	1652	intervention
O	1653	1661	resulted
O	1662	1664	in
O	1665	1671	better
O	1672	1680	outcomes
O	1681	1683	at
O	1684	1685	6
O	1686	1692	months
O	1692	1693	.

O	1694	1698	This
O	1699	1708	promising
O	1709	1714	pilot
O	1715	1720	trial
O	1721	1729	suggests
O	1730	1731	a
O	1732	1736	need
O	1737	1740	for
O	1741	1745	more
O	1746	1754	research
O	1755	1757	on
O	1758	1768	preventive
O	1769	1779	counseling
O	1780	1782	to
O	1783	1791	maintain
O	1792	1798	sexual
O	1799	1807	function
O	1808	1814	during
O	1815	1824	aromatase
O	1825	1834	inhibitor
O	1835	1844	treatment
O	1844	1845	.
